ICN 17261

Drug Profile

ICN 17261

Alternative Names: Levovirin; R 1270

Latest Information Update: 04 Nov 2004

Price : $50

At a glance

  • Originator Valeant Pharmaceuticals International
  • Class Antivirals; Nucleosides; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 04 Nov 2004 Data presented at the 55th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2004) have been added to the Viral Infections therapeutic trials section
  • 14 Nov 2003 ICN Pharmaceuticals is now called Valeant Pharmaceuticals International
  • 23 Oct 2003 Discontinued - Phase-II for Hepatitis C in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top